Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Barnes

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Blood Advances|September 27, 2023
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphomaReem Karmali, Jeremy S Abramson, Deborah M Stephens, et al.
International Journal of Radiation Oncology, Biology, Physics|April 3, 2025
5-5-5 ABRT (Dose of 5 Gy per Fraction for up to 5 Fractions Over 5 Weeks Adaptive Bridging Radiation Therapy)-Artificial Intelligence Enters the CAR (-T) (Chimeric Antigen Receptor-T) in Relapsed/Refractory Large B Cell LymphomaHazim S Ababneh, Andrea K Ng, Joshua Wan, et al.
Leukemia & Lymphoma|March 26, 2025
A phase-2 study of pembrolizumab in patients with biologically selected subtypes of relapsed/refractory aggressive lymphomasMwanasha H Merrill, Robert A Redd, David C Fisher, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 27, 2015
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk LymphomaYi-Bin Chen, Shuli Li, David C Fisher, et al.
Cancer|September 11, 2014
Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphomaYi-Bin Chen, Tracy Batchelor, Shuli Li, et al.
JACC. Heart Failure|July 28, 2022
Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With AnthracyclinesCarlos A Gongora, Zsofia D Drobni, Thiago Quinaglia Araujo Costa Silva, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 19, 2025
Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving ChemoimmunotherapyP Connor Johnson, Jeremy S Abramson, Ann S LaCasce, et al.
Blood Neoplasia|June 2, 2025
Short-duration infusion obinutuzumab with venetoclax in chronic lymphocytic leukemia: a prospective observational studyPriyanka Pullarkat, Matthew Lei, Robert Redd, et al.
Blood Advances|June 17, 2025
Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomasJosie G Ford, Min Jung Koh, Alexandra W Lenart, et al.
British Journal of Haematology|March 3, 2025
A low lymphocyte-to-monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysisPablo Mozas, Romain Ould Ammar, Loïc Chartier, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Blood Advances|September 27, 2023
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphomaReem Karmali, Jeremy S Abramson, Deborah M Stephens, et al.
International Journal of Radiation Oncology, Biology, Physics|April 3, 2025
5-5-5 ABRT (Dose of 5 Gy per Fraction for up to 5 Fractions Over 5 Weeks Adaptive Bridging Radiation Therapy)-Artificial Intelligence Enters the CAR (-T) (Chimeric Antigen Receptor-T) in Relapsed/Refractory Large B Cell LymphomaHazim S Ababneh, Andrea K Ng, Joshua Wan, et al.
Leukemia & Lymphoma|March 26, 2025
A phase-2 study of pembrolizumab in patients with biologically selected subtypes of relapsed/refractory aggressive lymphomasMwanasha H Merrill, Robert A Redd, David C Fisher, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 27, 2015
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk LymphomaYi-Bin Chen, Shuli Li, David C Fisher, et al.
Cancer|September 11, 2014
Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphomaYi-Bin Chen, Tracy Batchelor, Shuli Li, et al.
JACC. Heart Failure|July 28, 2022
Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With AnthracyclinesCarlos A Gongora, Zsofia D Drobni, Thiago Quinaglia Araujo Costa Silva, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 19, 2025
Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving ChemoimmunotherapyP Connor Johnson, Jeremy S Abramson, Ann S LaCasce, et al.
Blood Neoplasia|June 2, 2025
Short-duration infusion obinutuzumab with venetoclax in chronic lymphocytic leukemia: a prospective observational studyPriyanka Pullarkat, Matthew Lei, Robert Redd, et al.
Blood Advances|June 17, 2025
Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomasJosie G Ford, Min Jung Koh, Alexandra W Lenart, et al.
British Journal of Haematology|March 3, 2025
A low lymphocyte-to-monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysisPablo Mozas, Romain Ould Ammar, Loïc Chartier, et al.
Pageof 3